Protein protects liver against excess bileAugust 2nd, 2008 - 2:38 pm ICT by IANS
Washington, Aug 2 (IANS) Researchers have discovered a protein that controls genes maintaining proper level of bile in the liver. The protein, called FOXA2, is likely to become the focus for new therapies to treat diseases involvng regulation of bile salts.
Bile, made in the liver, is stored in the gall bladder and transported through ducts to the small intestine where it helps to digest fats from food.
Bile salts, chemicals in bile that help digest fats and also keep cholesterol dissolved in the bile, are reabsorbed from the intestine and returned to the liver where they are broken up.
The liver maintains a balance of bile salts by degrading old bile salts and synthesising new ones. Problems arise when too many bile salts accumulate in the liver.
Diseases of bile regulation, like primary sclerosing cholangitis (PSC), are characterised by problems with bile transport from the liver to the gut. Researchers found that in both children with biliary atresia and adults with PSC, expression of FOXA2 in the liver is severely reduced.
FOXA2 regulates expression of transporter proteins responsible for moving bile out of the liver, as well as several enzymes that function in bile acid detoxification. The study suggests that strategies to maintain FOXA2 expression might be a novel therapeutic goal.
In PSC, blockage of bile transport leads to inflammation of the bile duct and, over time, liver damage. The causes of PSC and related syndromes are not known, but may be autoimmune-related.
PSC is associated with an increased risk of liver cirrhosis and liver cancer. Biliary atresia is a birth defect in which the bile ducts do not have normal openings, preventing bile from leaving the liver. The condition causes jaundice and cirrhosis of the liver.
Senior author Klaus Kaestner, professor of genetics, named the family of FOX genes and previous work in his lab showed that FOXA2 was important for glucose metabolism in the liver.
“Our interest in using genomics to study metabolic diseases led us to screen DNA from liver cells that expressed FOXA2 with an assay called ChIP on Chip,” explained co-author Irina Bochkis, of the Institute for Diabetes, Obesity, and Metabolism at Pennsylvania School of Medicine.
Chip-on-Chip assay stands for Chromatin ImmunoPrecipitation on a gene chip.
The study was published online this week in Nature Medicine.
- ''Foxy old gene'' offers therapeutic target for liver diseases - Aug 02, 2008
- Study sheds new light on the causes of chronic liver cirrhosis - Mar 14, 2011
- Immune system's natural killer cells linked to infant liver disease - Jul 23, 2009
- Chinese moms to donate liver to each other's kids - Sep 12, 2012
- Cholesterol regulator plays key role in development of liver fibrosis - Mar 31, 2011
- Marathon liver transplant saves three toddlers (with Images) - Jan 17, 2012
- Curcumin could slow liver disease: Study - Mar 26, 2010
- Potential new non-insulin treatment for type 1 diabetes found - Mar 25, 2011
- Protein that controls liver stem cells, prevents tumor development found - Aug 13, 2010
- Chronic liver disease cure on the horizon - Mar 06, 2012
- A drug that relieves you of constipation - May 11, 2011
- Master regulator gene's discovery takes scientists a step closer to possible diabetes cure - Jul 21, 2009
- Potential new target for diabetes treatment identified - Nov 03, 2010
- Why some people develop medical complications of obesity while others don't - Mar 11, 2011
- Vitamin E can fight fatty liver disease in kids - Apr 28, 2011
Tags: aug 2, bile acid, bile ducts, bile salts, biliary atresia, birth defect, detoxification, gall bladder, glucose metabolism, inflammation of the bile duct, kaestner, liver cancer, liver cirrhosis, liver damage, liver diseases, primary sclerosing cholangitis psc, small intestine, syndromes, therapeutic goal, transporter proteins